Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers
| Autor: | Lee, Jong W., Pussegoda, Kusala, Rassekh, Shahrad R., Monzon, Jose G., Liu, Geoffrey, Hwang, Soomi, Bhavsar, Amit P., Pritchard, Sheila, Ross, Colin J., Amstutz, Ursula, Carleton, Bruce C., Hayden, Michael R., MacLeod, Stuart, Smith, Anne, Brunham, Liam, Aminkeng, Folefac, Shear, Neil H., Koren, Gideon, Ito, Shinya, Madadi, Parvaz, Rieder, Michael J., Kim, Richard, Maher, Maurica, Flockhart, David |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Genetic Markers
0301 basic medicine medicine.medical_specialty Hearing loss clinical practice recommendations Alternative medicine MEDLINE cisplatin Antineoplastic Agents 610 Medicine & health Context (language use) Bioinformatics 03 medical and health sciences 0302 clinical medicine medicine Humans Pharmacology (medical) Hearing Loss Intensive care medicine hearing loss Pharmacology Cisplatin Polymorphism Genetic pharmacogenetic testing business.industry Clinical Practice 030104 developmental biology ototoxicity Pharmacogenetics 030220 oncology & carcinogenesis Pharmacogenomics medicine.symptom business medicine.drug |
| Zdroj: | Paediatrics Publications Lee, Jong W; Pussegoda, Kusala; Rassekh, Rod S; Monzon, Jose G; Liu, Geoffrey; Hwang, Soomi; Bhavsar, Amit P; Pritchard, Sheila; Ross, Colin J; Carleton, Bruce C; Amstutz, Ursula (2016). Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Therapeutic drug monitoring, 38(4), p. 1. Lippincott Williams & Wilkins 10.1097/FTD.0000000000000298 |
| DOI: | 10.1097/FTD.0000000000000298 |
| Popis: | Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|